uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies

Inclusion criteria

• ✓. Age ≥18 and \<70 years, regardless of gender;
• ✓. T-ALL/LBL was diagnosed according to the criteria of NCCN Clinical Practice Guidelines for Acute Lymphocytic Leukemia (2020.v1) and T-cell Lymphoma Clinical Practice Guidelines (2020.v1);
• ✓. Patients diagnosed with AML with reference to the Guidelines for Diagnosis and Treatment of Adult Acute Myeloid Leukemia (2018 Edition) issued by the Health Commission;
• ✓. Cytology confirmed that the tumor cells were CD7 positive.
• ✓. Number of blasts in bone marrow ≥5% at screening (bone marrow morphology);
• ✓. Complies with the diagnosis of relapsed/refractory AML, including any of the following conditions according to China Guidelines for Diagnosis and Treatment of Relapsed/Refractory Acute Myeloid Leukemia (2021 Edition):
• ✓. Primary refractory patients who did not achieve CR after two cycles of standard induction chemotherapy;
• ✓. CR after consolidation chemotherapy, relapse within 12 months;

Exclusion criteria